Latest Conference Articles

Approximately 30% of annual HIV infections are caused by the subset of individuals unaware of their serostatus, and HCV rates have nearly tripled since 2011.

Pauline Funchain MD, shares how artificial intelligence may serve as a potential breakthrough for treating rare diseases in the future.

E. Anders Kolb, MD, discusses the exciting possibilities of using genomic technologies to stratify pediatric cancer patients.

Pauline Funchain MD, explains how better understanding of genetics can help shape future treatments for rare cancers.

Manmeet Ahluwalia, MD, discusses the challenges patients and providers face when it comes to rare cancers.

How come treat-and-extend may not be the most ideal therapy regimen for retina disease, and how biologics change physicians' perspective on dosing.

Are anti-VEGF and PRP therapies the best-case scenario for patients with AMD, or will gene therapies reach the market in the near future?

How the three-year results of a gene therapy for inherited retinal disease may redefine its potential in ophthalmology.

Patients who were treated with CLS-TA were able to achieve ≥3 lines of visual acuity 47% of the time, compared to 15% of the patients who received sham treatment.

After 6 months, 80% of those implanted with the 100 mg/mL dose of ranibizumab still did not need a medication refill.

A comparison of patients with either anterior segment neovascularization without glaucoma or neovascular glaucoma found the benefits of anti-VEGF and PRP are heavily influenced by the presence of glaucoma.

A three-year update of VN for patients with biallelic RPE65 mutation-associated inherited retinal disease improved on the common standard-of-care for retina disease.

Results from the PACORES group clinical trial debunked previously-held beliefs that IVB is unsafe for patients with proliferative diabetic retinopathy undergoing the procedure.

Why substantial evidence is lacking to indicate either therapy method's preference for the treatment of neovascularization.

The use of a single drop of nepafenac 0.3% suspension has shown in a trial to be an effective pain reducer post-intravitreal injection at both 6-hour and 24-hour points.

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”

E. Anders Kolb, MD, outlines the challenges in diagnosing pediatric cancers and explains how molecular events define disease outcomes.

The modeled and lifetime QALY costs in the facility and out of the facility were $181,144 and $107,965, respectively, for PPV.

A population-based cohort study identified that patients with insomnia developed AMD at a rate 0.7% higher than those who did not.

How improvements to patient education, drug costs, and biosimilar therapy availability could keep patients with retina disease away from risky procedures.

Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.

The number of anti-VEGF injections patients underwent per 28 days decreased from 0.322 to 0.047 after FAc implantation.

The director of the Section of Uveitis and Vasculitis at Emory University spoke about the potential of this novel delivery method in conditions such as uveitis and retinal vein occlusion.

Researchers found testing is significantly more practiced by patients offered it in person, versus those referred, with little difference found in mutation identification.

Though cell therapies have gained FDA approval to treat any ocular disease, companies have marketed predominately to patients with AMD, with procedures that could lead to blindness.

Though the 2 dosing regimens had comparable visual acuity improvements over 24 months, patients given ranibizumab once-monthly received treatment nearly 6 more times on average.

The treatment, traditionally used for cancer, not only improved BVCA measurements but also resulted in the number of injections patients needed.